TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+13.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.46B
AUM Growth
+$2.46B
(+5.4%)
Cap. Flow
-$90.4M
Cap. Flow
% of AUM
-3.67%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
213
New
10
Increased
47
Reduced
70
Closed
17
Top Buys
| 1 |
Pfizer
PFE
|
$23.5M |
| 2 |
Merck
MRK
|
$21.2M |
| 3 |
Welltower
WELL
|
$14.9M |
| 4 |
Eli Lilly
LLY
|
$10.2M |
| 5 |
CELG
Celgene Corp
CELG
|
$8.65M |
Top Sells
| 1 |
Biogen
BIIB
|
$19.1M |
| 2 |
Johnson & Johnson
JNJ
|
$18.8M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.3M |
| 4 |
AbbVie
ABBV
|
$13.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
$13.5M |
Sector Composition
| 1 | Healthcare | 94.43% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Stryker
SYK
$149B
| $24.3M | 0.99% |
123,050
-37,382
| -23% | -$7.38M |
|
27
Intuitive Surgical
ISRG
$158B
| $23M | 0.93% |
40,281
+1,052
| +3% | +$600K |
|
|
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
| $21.2M | 0.86% |
289,925
+63,686
| +28% | +$4.66M |
|
29
Danaher
DHR
$143B
| $21M | 0.85% |
158,931
-50,440
| -24% | -$6.66M |
|
30
BioMarin Pharmaceuticals
BMRN
$11.3B
| $19.7M | 0.8% |
222,086
+14,652
| +7% | +$1.3M |
|
31
Neurocrine Biosciences
NBIX
$13.5B
| $19.5M | 0.79% |
221,678
+5,384
| +2% | +$474K |
|
32
Cigna
CI
$80.2B
| $18.8M | 0.76% |
116,756
+52,667
| +82% | +$8.47M |
|
|
33
Welltower
WELL
$112B
| $18.4M | 0.75% |
237,322
+191,762
| +421% | +$14.9M |
|
34
Boston Scientific
BSX
$159B
| $18.2M | 0.74% |
473,619
+28,628
| +6% | +$1.1M |
|
35
Sarepta Therapeutics
SRPT
$1.98B
| $17.6M | 0.72% |
147,847
-43,990
| -23% | -$5.24M |
|
36
Exelixis
EXEL
$9.95B
| $16.1M | 0.66% |
678,467
+339,032
| +100% | +$8.07M |
|
|
PRAH
37
DELISTED
PRA Health Sciences, Inc.
PRAH
| $15.8M | 0.64% |
143,537
+73,077
| +104% | +$8.06M |
|
38
Becton Dickinson
BDX
$54.3B
| $15.4M | 0.63% |
61,721
-8,057
| -12% | -$2.01M |
|
39
AstraZeneca
AZN
$255B
| $14.6M | 0.59% |
360,998
-67,026
| -16% | -$2.71M |
|
|
BLUE
40
DELISTED
bluebird bio
BLUE
| $14.3M | 0.58% |
91,029
-7,400
| -8% | -$1.17M |
|
41
Idexx Laboratories
IDXX
$50.7B
| $14.2M | 0.58% |
63,654
+12,079
| +23% | +$2.7M |
|
42
Teva Pharmaceuticals
TEVA
$21.5B
| $14M | 0.57% |
890,989
-320,879
| -26% | -$5.03M |
|
43
Novo Nordisk
NVO
$252B
| $13.2M | 0.53% |
251,600
-50,300
| -17% | -$2.63M |
|
44
Omega Healthcare
OHI
$12.5B
| $13M | 0.53% |
340,266
-39,856
| -10% | -$1.52M |
|
|
SAGE
45
DELISTED
Sage Therapeutics
SAGE
| $12.7M | 0.52% |
79,856
-18,588
| -19% | -$2.96M |
|
|
AMRN
46
Amarin Corp
AMRN
$311M
| $12.7M | 0.52% |
611,352
-42,700
| -7% | -$886K |
|
|
ONC
47
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $12.5M | 0.51% |
94,889
+9,134
| +11% | +$1.21M |
|
48
Alnylam Pharmaceuticals
ALNY
$58.6B
| $12.5M | 0.51% |
133,458
+7,282
| +6% | +$681K |
|
49
HCA Healthcare
HCA
$95.4B
| $11.7M | 0.47% |
89,569
+15,234
| +20% | +$1.99M |
|
50
Baxter International
BAX
$12.1B
| $11.2M | 0.45% |
137,668
-23,565
| -15% | -$1.92M |
|